387 related articles for article (PubMed ID: 22212565)
1. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
European Association of the Study of the Liver
Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
[TBL] [Abstract][Full Text] [Related]
2. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
5. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
6. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
Francioso S; Almerighi C; Forte P; Bandiera F; Nosotti L; Lionetti R; Taliani G; Piras MR; Ponti ML; Parruti G; Di Candilo F; Gentile S; Piccolo P; Salso A; Riccobelli F; Renzi S; Longo MA; Montalbano M; Zaru S; Biliotti E; Di Masi F; Santopaolo F; Angelico M
Dig Liver Dis; 2014 Feb; 46(2):164-9. PubMed ID: 24239044
[TBL] [Abstract][Full Text] [Related]
7. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
8. How to optimize HCV therapy in genotype 2 patients.
Grassi E; Aghemo A
Liver Int; 2013 Feb; 33 Suppl 1():35-40. PubMed ID: 23286844
[TBL] [Abstract][Full Text] [Related]
9. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C treatment in näive patients.
Daruich J
Ann Hepatol; 2010; 9 Suppl():65-71. PubMed ID: 20713999
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Giannini EG; Basso M; Savarino V; Picciotto A
J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
[TBL] [Abstract][Full Text] [Related]
12. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
13. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
Ackefors M; Castedal M; Dahlgard O; Verbaan H; Gjertsen H; Wernerson A; Weiland O
Infect Dis (Lond); 2015 Apr; 47(4):209-17. PubMed ID: 25650729
[TBL] [Abstract][Full Text] [Related]
14. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
15. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.
Lagging M; Rembeck K; Rauning Buhl M; Christensen P; Dalgard O; Färkkilä M; Hellstrand K; Langeland N; Lindh M; Westin J; Norkrans G
Scand J Gastroenterol; 2013 Jul; 48(7):839-47. PubMed ID: 23795661
[TBL] [Abstract][Full Text] [Related]
16. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
17. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
19. How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Bourlière M; Wendt A; Fontaine H; Hézode C; Pol S; Bronowicki JP
Liver Int; 2013 Feb; 33 Suppl 1():46-55. PubMed ID: 23286846
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]